Gastrodia elata Polysaccharide Attenuates Aging in Mice via Modulation of Oxidative Stress, Inflammation, and Gut Microbiota
In a D-galactose-induced murine aging model, Gastrodia elata polysaccharide reduced oxidative stress and inflammatory markers and shifted gut microbiota composition favorably, but no evidence of efficacy in humans exists.
| Population | Mice with D-galactose-accelerated aging (preclinical model) |
|---|---|
| Intervention | Gastrodia elata polysaccharide (GEP) administered orally at multiple doses |
| Comparator | Negative control group (no D-galactose) and positive model group (D-galactose without GEP) |
| Outcome | Serum oxidative stress (SOD, MDA, CAT, GSH-Px); Serum inflammatory cytokines (TNF-α, IL-6, IL-1β); Intestinal barrier integrity (occludin, claudin-1, ZO-1); Gut microbiota composition (Lactobacillus, Bifidobacterium, Bacteroidetes, Proteobacteria) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Serum oxidative stress (SOD, MDA, CAT, GSH-Px) | Direction favorable vs model group; absolute values and 95% CI not reported | — | Very low | — | 1 studies |
| Serum inflammatory cytokines (TNF-α, IL-6, IL-1β) | Direction favorable vs model group; absolute values and 95% CI not reported | — | Very low | — | 1 studies |
| Intestinal barrier integrity (occludin, claudin-1, ZO-1) | Direction favorable vs model group; absolute values and 95% CI not reported | — | Very low | — | 1 studies |
| Gut microbiota composition (Lactobacillus, Bifidobacterium, Bacteroidetes, Proteobacteria) | Relative abundance shift favorable vs model group; 16S rRNA; absolute values and 95% CI not reported | — | Very low | — | 1 studies |
Context
Aging is accelerated by the interplay of oxidative stress, chronic low-grade inflammation, and gut dysbiosis. Plant-derived compounds with antioxidant and immunomodulatory activity represent an active research line. Polysaccharides from medicinal plants have shown effects in animal models, but translation to humans remains unestablished.
What the study showed
GEP increased SOD, CAT, and GSH-Px activity and reduced MDA in serum of aged mice compared to the model group, with a favorable direction for antioxidant markers. It reduced serum TNF-α, IL-6, and IL-1β. It increased expression of tight junction proteins (occludin, claudin-1, ZO-1). In the microbiota, it increased relative abundance of Lactobacillus and Bifidobacterium and reduced Bacteroidetes and Proteobacteria. Absolute values, 95% CIs, and effect sizes were not reported in the provided text.
How it was done
Preclinical in vivo experimental study in mice. Accelerated aging was induced by subcutaneous D-galactose injection. Animals received GEP by oral gavage at multiple doses. Serum biochemical parameters, tissue histology, protein expression, and 16S rRNA gut microbiota sequencing were assessed. Exact duration and number of animals per group were not specified in the provided extract.
Effect magnitude
Absolute effect values, 95% CIs, and effect size measures (SMD, MD, RR) were not reported in the available text; magnitude cannot be precisely quantified from provided data.
Risk of bias
Animal model (D-galactose in mice) with very limited external validity for humans. Absence of 95% CIs, effect sizes, and exact animal numbers per group precludes quantitative bias risk assessment (SYRCLE or ARRIVE tools not mentioned). Causal mechanism between microbiota alteration and anti-aging effect is not established; only associations were demonstrated.
What this study does NOT prove
This study does not prove anti-aging efficacy in humans nor establishes causality between GEP-driven microbiota modulation and aging retardation. Results in a D-galactose murine accelerated aging model are not generalizable to human physiological aging.
In clinical practice
No clinical recommendation can be derived from this study. Healthcare professionals should not recommend GEP as an anti-aging intervention based on these data. The study generates hypotheses for future clinical trials.
Limitations
Animal model (D-galactose in mice) with very limited external validity for humans. Absence of 95% CIs, effect sizes, and exact animal numbers per group precludes quantitative bias risk assessment (SYRCLE or ARRIVE tools not mentioned). Causal mechanism between microbiota alteration and anti-aging effect is not established; only associations were demonstrated.
What is still missing
Randomized clinical trials in humans with clinically relevant outcomes (morbidity, functionality, quality of life) and long-term safety assessment. Dose-response and oral bioavailability studies in humans are needed.
Technical appendix
Version history
- 1.0 · 2026-11-10 — Auto-generated under Evidence Standard v1.0